Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07654842 · ClinicalTrials.gov registry record · Phase 4
Fasenra: An Asthma Study
A Phase 4 study, sponsored by Endeavor Health.
- Not yet
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT07654842: Clinical Trial Phase 4 study, sponsored by Endeavor Health.
NCT07654842 is a Phase 4 study that has not yet begun recruiting, run by Endeavor Health. The registered enrollment target is 40 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07654842, a Phase 4 study, has not yet begun recruiting, sponsored by Endeavor Health.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in people with severe eosinophilic asthma. Participants will have electronic medication monitors fitted to their usual maintenance inhaler, as well as a study-provided anti-inflammatory rescue inhaler, albuterol-budesonide (AirSupra). These monitors will track when each inhaler is used. Participants will also upload time-stamped photos of their benralizumab administration to their electronic medical records.
Primary Outcome
Difference between ICS-SABA uses in the first and last two weeks of the 3rd of 3 benralizumab dosing cycles during the study period.
Interventions
- DRUG Benralizumab
- DRUG Budesonide-albuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2028-01-01 |
| Phase | Phase 4 |
What is known before NCT07654842 opens enrollment
NCT07654842 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Benralizumab is the first listed.
NCT07654842 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07654842 about?
NCT07654842 is a clinical study titled "Fasenra: An Asthma Study". The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in people with severe eosinophilic asthma. Participants will have electronic medication monitors fitted to their usual maintenance inhaler, as w...
What is the current status of trial NCT07654842?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2026-07-01. Estimated completion is 2028-01-01.
What interventions are being tested in trial NCT07654842?
The interventions under investigation include: Benralizumab (DRUG), Budesonide-albuterol (DRUG).
Who is sponsoring clinical trial NCT07654842?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07654842's enrollment target sits among peer trials
40 1397th of 2000 higher than 533 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI